Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Lasers in Medical Science

18.07.2020 | Original Article

Evaluating the efficacy and safety of vascular IPL for treatment of acute cutaneous leishmaniasis: a randomized controlled trial

Erschienen in: Lasers in Medical Science | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Treatment of cutaneous leishmaniasis (CL) continues to be a health concern, and alternative therapies with fewer side effects are substantially needed. This study aimed to determine the efficacy of intense pulsed light (IPL) with wavelength spectrum affecting vascular lesions on acute cutaneous leishmaniasis. In this randomized clinical trial study, 30 patients with acute CL were enrolled. Baseline clinical and demographic data were recorded in the checklist after obtaining written informed consent. Patients were randomly allocated to receive either IPL fortnightly (intervention group) or intralesional meglumine antimoniate (MA) weekly (control group) over 10 weeks. Patients were assessed every 2 weeks to determine the size of induration and improvement rate of lesions. Follow-up visits were arranged at 3rd and 6th months. Overall, 15 patients (21 lesions) in the intervention group and 15 patients (22 lesions) in the control group were studied. The size of lesions in the control group was significantly higher at the baseline (P = 0.014) and the second week (P = 0.034), and significantly lower in the eighth week (P = 0.009), compared with the intervention group. The size of lesions in the control group changed during the study (P < 0.001), whereas changes were not significant in the intervention group. The trend of changes in size of lesions was faster in the control group (P < 0.001). More patients in the control group had higher improvement rate at the sixth (P = 0.005) and tenth (P < 0.001) weeks. At the end of study, the cure rate was 35% (7 out of 20 lesions) in intervention group and 81.8% (18 out of 22 lesions) in the control group. Complete response happened earlier in the control group (P < 0.001). None of the lesions that were cured before the tenth week relapsed after 6 months. The frequency of blistering was significantly higher in intervention group (P = 0.001). Our results indicated that IPL with wavelength spectrum affecting vascular lesions was inferior to intralesional MA in treatment of CL. However, it can be considered as a second-line option, especially in patients with limitations for use of MA. Trial registry: https://​www.​irct.​ir/​trial/​34246 IRCT20140414017271N5
Literatur
1.
Norouzinezhad F, Ghaffari F, Norouzinejad A, Kaveh F, Gouya MM (2016) Cutaneous leishmaniasis in Iran: results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed 6(7):614–619CrossRef
2.
de Vries HJC, Reedijk SH, Schallig HDFH (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol 16(2):99–109CrossRef
3.
Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M (2016) Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 16(5):584–591CrossRef
4.
Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review 2017;12(9):e0184777
5.
Savioli L, Velayudhan R (2014) Small bite, big threat: World Health Day 2014. East Mediterr Health J 20(4):217–218CrossRef
6.
Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, Lopez-Velez R, Garcia-Hernandez R et al (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 11(12):e0006052CrossRef
7.
Elsaie ML, Ibrahim SM (2018) The effect of pulsed dye laser on cutaneous leishmaniasis and its impact on the Dermatology Life Quality Index. J Cosmet Laser Ther 20(3):152–155CrossRef
8.
Nouri K, Elsaie ML, Vejjabhinanta V, Stevens M, Patel SS, Caperton C et al (2010) Comparison of the effects of short- and long-pulse durations when using a 585-nm pulsed dye laser in the treatment of new surgical scars. Lasers Med Sci 25(1):121–126CrossRef
9.
Radmanesh M, Omidian E (2017) The pulsed dye laser is more effective and rapidly acting than intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. J Dermatol Treat 28(5):422–425CrossRef
10.
Slaoui W, Chiheb S, Benchikhi H (2015) Efficacy of pulsed-dye laser on residual red lesions of cutaneous leishmaniasis. Ann Dermatol Venereol 142(1):17–20CrossRef
11.
Wat H, Wu DC, Rao J, Goldman MP (2014) Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. Dermatol Surg 40(4):359–377CrossRef
12.
Babilas P, Schreml S, Szeimies RM, Landthaler M (2010) Intense pulsed light (IPL): a review. Lasers Surg Med 42(2):93–104CrossRef
13.
Minodier P, Parola P (2007) Cutaneous leishmaniasis treatment. Travel Med Infect Dis 5(3):150–158CrossRef
14.
Shamsi Meymandi S, Zandi S, Aghaie H, Heshmatkhah A (2011) Efficacy of CO2 laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J Eur Acad Dermatol Venereol 25(5):587–591CrossRef
15.
Omi T, Kawana S, Sato S, Takezaki S, Honda M, Igarashi T et al (2005) Cutaneous immunological activation elicited by a low-fluence pulsed dye laser. Br J Dermatol 153(Suppl 2):57–62CrossRef
16.
Rodriguez M, Inguanzo P, Ramos A, Perez J (1990) Treatment of cutaneous leishmaniasis with CO2 laser radiation. Rev Cubana Med Trop 42(2):197–202PubMed
17.
Sadeghian G, Nilfroushzadeh MA, Iraji F (2007) Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 32(4):371–374CrossRef
18.
Vega JC, Sanchez BF, Montero LM, Montana R, Mahecha Mdel P, Duenes B et al (2009) The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting. Trans R Soc Trop Med Hyg 103(7):703–706CrossRef
19.
Mashayekhi Goyonlo V, Karrabi M, Kiafar B (2019) Efficacy of erbium glass laser in the treatment of Old World cutaneous leishmaniasis: a case series. Australas J Dermatol 60(1):e29–e32CrossRef
20.
Rogers NE, Avram MR (2012) Vascular lasers and lights. In: Alam M (ed) Evidence-based procedural dermatology. Springer New York, New York, pp 215–234CrossRef
21.
Tremaine AM, Avram MM (2015) FDA MAUDE data on complications with lasers, light sources, and energy-based devices. Lasers Surg Med 47(2):133–140CrossRef
Metadaten
Titel
Evaluating the efficacy and safety of vascular IPL for treatment of acute cutaneous leishmaniasis: a randomized controlled trial
Publikationsdatum
18.07.2020
Erschienen in
Lasers in Medical Science / Ausgabe 3/2021
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-020-03102-2